Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tilmann Bochtler

Showing results (51-60 of 52) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 52 results.
Blood|December 8, 2025
Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trialAnne Sophie Platzbecker, Julia Annabell Georgi, Jan Moritz Middeke, et al.
Blood Advances|March 26, 2020
RUNX1-mutated families show phenotype heterogeneity and a somatic mutation profile unique to germline predisposed AMLAnna L Brown, Peer Arts, Catherine L Carmichael, et al.
Pageof 6

Showing results (51-60 of 52) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 52 results.
Blood|December 8, 2025
Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trialAnne Sophie Platzbecker, Julia Annabell Georgi, Jan Moritz Middeke, et al.
Blood Advances|March 26, 2020
RUNX1-mutated families show phenotype heterogeneity and a somatic mutation profile unique to germline predisposed AMLAnna L Brown, Peer Arts, Catherine L Carmichael, et al.
Pageof 6